Revolution Medicines' Cancer Win Makes Royalty Pharma a Steal

Revolution Medicines (RVMD) has received FDA approval for its pancreatic cancer drug daraxonrasib, a major milestone that sent its stock soaring. The company has invested heavily in developing this treatment, and now it stands on the verge of potentially massive profits.

Royalty Pharma (RPRX), which provided financing to Revolution Medicines in exchange for royalties on the drug's sales, estimates that daraxonrasib could achieve peak annual revenues of $11 billion. That would easily make it a blockbuster drug and a huge win for Revolution Medicines.

Investors have taken notice: RVMD stock is up 200% over the past year and more than 700% over the past three years, reflecting high expectations for the drug's commercial success.

But while Revolution Medicines grabs the headlines, Royalty Pharma stands to benefit quietly. As a royalty financing company, Royalty Pharma doesn't develop drugs itself; instead, it funds drug development in exchange for a percentage of future sales. For daraxonrasib, Royalty Pharma could see peak royalties of up to $340 million.

Royalty Pharma's business model is diversified: it has investments in 35 approved drugs (16 of which are blockbusters) and 16 more in development, with an average remaining royalty period of 13 years. This gives investors exposure to a broad portfolio of drug royalties without the risks of drug development.

The FDA approval of daraxonrasib is a game-changer for Revolution Medicines, but the stock has already priced in a lot of good news. After a 700% run over three years, much of the upside may already be reflected in the share price. Moreover, Revolution Medicines is still a single-drug story with high risk: if daraxonrasib disappoints in the market or faces competition, the stock could suffer.

Royalty Pharma, on the other hand, offers a diversified way to invest in the same success. Its royalty stream from daraxonrasib is just one of many, and the company's portfolio includes blockbuster drugs across various therapeutic areas. This diversification reduces risk and provides a steady income stream.

Additionally, Royalty Pharma pays a dividend yield of 1.4%, making it attractive for income-oriented investors. The company's business model is less capital-intensive than traditional pharma, as it doesn't bear the costs of drug development or commercialization.

For investors who want exposure to the potential of daraxonrasib without the volatility of a single stock, Royalty Pharma is a compelling alternative. It allows you to participate in the drug's success while benefiting from a broader portfolio of royalties.